 |
 |
Please
click for information on US Patent:
U.S. Patent no: 6,090,625 |
|
United
States Patent Application |
20010024826 |
|
Kind Code |
A1 |
|
Inventors: |
Abuljadayel,
Ilham Saleh; (London, GB) |
|
Assignee
Name |
DHOOT, GHAZI
JASWINDER |
|
Serial
No.: |
742520 |
|
Series
Code: |
09 |
|
Filed |
December 20,
2000 |
|
U.S.
Current Class: |
435/372;
435/34; 435/372.2; 435/7.1; 435/7.21; 436/501 |
|
U.S.
Class at Publication: |
435/372;
435/372.2; 435/7.1; 435/7.21; 435/34; 436/501 |
|
Intern'l
Class: |
C12N 005/08;
G01N 033/53; G01N 033/567; C12Q 001/04; G01N 033/566 |
|
Foreign Application Data
|
|
Date |
Feb 2, 1995 |
|
Code |
GB |
|
Application
Number |
9502022.8 |
|
Abstract |
|
A method of
preparing an undifferentiated cell is described. The
method comprises contacting a more committed cell with an
agent that causes the more committed cell to
retrodifferentiate into an undifferentiated cell. |
|
Claims |
1. A method
of preparing an undifferentiated cell, the method
comprising contacting a more committed cell with an agent
that causes the more committed cell to retrodifferentiate
into an undifferentiated cell.
2. A method according to claim 1 wherein the more
committed cell is capable of retrodifferentiating into an
MHC Class I.sup.+ and/or an MHC Class II.sup.+
undifferentiated cell.
3. A method according to claim 1 or claim 2 wherein the
more committed cell is capable of retrodifferentiating
into an undifferentiated cell comprising a stem cell
antigen.
4. A method according to any one of the preceding claims
wherein the more committed cell is capable of
retrodifferentiating into a CD34.sup.+ undifferentiated
cell.
5. A method according to any one of the preceding claims
wherein the more committed cell is capable of
retrodifferentiating into a lymphohaematopoietic
progenitor cell.
6. A method according to any one of the preceding claims
wherein the more committed cell is capable of
retrodifferentiating into a pluripotent stem cell.
7. A method according to any one of the preceding claims
wherein the undifferentiated cell is an MHC Class I.sup.+
and/or an MHC Class II.sup.+ cell.
8. A method according to any one of the preceding claims
wherein the undifferentiated cell comprises a stem cell
antigen.
9. A method according to any one of the preceding claims
wherein the undifferentiated cell is a CD34.sup.+
undifferentiated cell.
10. A method according to any one of the preceding claims
wherein the undifferentiated cell is a
lymphohaematopoietic progenitor cell.
11. A method according to any one of the preceding claims
wherein the undifferentiated cell is a pluripotent stem
cell.
12. A method according to any one of the preceding claims
wherein the more committed cell is an MHC Class I.sup.+
and/or an MHC Class II.sup.+ cell.
13. A method according to any one of the preceding claims
wherein the agent acts extracelluarly of the more
committed cell.
14. A method according to any one of the preceding claims
wherein the more committed cell comprises a receptor that
is operably engageable by the agent and wherein the agent
operably engages the receptor.
15. A method according to claim 14 wherein the receptor is
a cell surface receptor.
16. A method according to claim 14 or claim 15 wherein the
receptor comprises an .alpha.-component and/or a
.beta.-component.
17. A method according to claim 16 wherein the receptor
comprises a .beta.-chain having homologous regions.
18. A method according to claim 17 wherein the receptor
comprises at least the homologous regions of the
.beta.-chain of HLA-DR.
19. A method according to claim 16 wherein the receptor
comprises an .alpha.-chain having homologous regions.
20. A method according to claim 19 wherein the receptor
comprises at least the homologous regions of the
.alpha.-chain of HLA-DR.
21. A method according to any one of claims 14 to 20
wherein the agent is an antibody to the receptor.
22. A method according to claim 21 wherein the agent is a
monoclonal antibody to the receptor.
23. A method according to claim 18 wherein the agent is an
antibody, preferably a monoclonal antibody, to the
homologous regions of the .beta.-chain of HLA-DR.
24. A method according to claim 20 wherein the agent is an
antibody, preferably a monoclonal antibody, to the
homologous regions of the .alpha.-chain of HLA-DR.
25. A method according to any one of the preceding claims
wherein the agent modulates MHC gene expression,
preferably wherein the agent modulates MHC Class I.sup.+
and/or MHC Class II.sup.+ expression.
26. A method according to any one of the preceding claims
wherein the agent is used in conjunction with a biological
response modifier.
27. A method according to claim 25 wherein the biological
response modifier is an alkylating agent, preferably
wherein the alkylating agent is or comprises
cyclophosphoamide.
28. A method according to any one of the preceding claims
wherein the more committed cell is a differentiated cell.
29. A method according to claim 28 wherein the more
committed cell is any one of a B cell or a T cell.
30. A method according to any one of claims 1 to 27
wherein the more committed cell is a more mature
undifferentiated cell.
31. A method according to any one of the preceding claims
wherein the undifferentiated cell is committed to a
recommitted cell.
32. A method according to claim 31 wherein the recommitted
cell is of the same lineage as the more committed cell
prior to retrodifferentiation.
33. A method according to claim 31 wherein the recommitted
cell is of a different lineage as the more committed cell
prior to retrodifferentiation.
34. A method according to any one of claims 31 to 33
wherein the recommitted cell is any one of a B cell, a T
cell or a granulocyte.
35. A method according to any one of the preceding claims
wherein the method is an in vitro method.
36. An undifferentiated cell produced according to the
method of any one of claims 1 to 35.
37. An undifferentiated cell produced according to the
method of any one of claims 1 to 35 for use as or in the
preparation of a medicament.
38. Use of an undifferentiated cell produced according to
the method of any one of claims 1 to 37 in the manufacture
of a medicament for the treatment of an immunological
disorder or disease.
39. A recommitted cell produced according to the method of
any one of claims 31 to 35.
40. A recommitted cell produced according to the method of
any one of claims 31 to 35 for use as or in the
preparation of a medicament.
41. Use of a recommitted cell produced according to the
method of any one of claims 31 to 35 in the manufacture of
a medicament for the treatment of an immunological
disorder or disease.
42. A more committed cell having attached thereto an agent
that can cause the more committed cell to
retrodifferentiate into an undifferentiated cell.
43. A CD19.sup.+ and CD3.sup.+ cell.
44. A method of preparing an undifferentiated cell from a
more committed cell substantially as hereinbefore
described.
45. An undifferentiated cell prepared from a more
committed cell substantially as hereinbefore described.
46. A recommitted cell prepared from an undifferentiated
cell which has been prepared from a more committed cell
substantially as hereinbefore described.
|
|
 |
 |
|
